Monthly Injectable Buprenorphine Shows Strong Real-World Results for Opioid Use Disorder Remission

New real-world evidence presented at the American Society of Addiction Medicine (ASAM) 2026 Annual Conference adds to the growing body of research supporting extended-release buprenorphine as an effective treatment option for opioid use disorder, with data showing it accounts for the smallest proportion of overdose events compared to other medications and no treatment at all.

The findings, presented by Indivior Pharmaceuticals in collaboration with Virginia Tech researchers, come from two separate studies that examined overdose outcomes and treatment remission among patients receiving monthly injectable buprenorphine, commercially available as Sublocade. With more than 500,000 people now prescribed the long-acting formulation, the accumulating evidence suggests the medication is delivering meaningful results in clinical practice beyond what controlled trials alone could demonstrate.

Ontario Study Links Medication Coverage to Overdose Risk Reduction

A retrospective nested case-control study conducted in Ontario, Canada analyzed administrative health data from more than 45,000 patients with opioid use disorder to evaluate associations between different medication-assisted treatments and the risk of fatal and non-fatal overdose. The study compared outcomes among patients receiving extended-release buprenorphine, transmucosal buprenorphine, methadone, and sustained-release oral morphine.

The results revealed a clear pattern: most overdose events occurred when patients were off treatment entirely. Among those who remained engaged with medication-assisted treatment, patients with higher coverage—defined as being on medication more than 80 percent of the time—experienced significantly fewer non-fatal and fatal overdoses compared to those with lower coverage rates.

Most notably, the study found that of all medications for opioid use disorder, monthly extended-release buprenorphine accounted for the smallest proportion of both non-fatal and fatal overdose events when compared to no treatment. This finding reinforces earlier clinical trial data suggesting the long-acting formulation may offer protective benefits through consistent medication delivery without the daily adherence challenges that can compromise oral formulations.

Remission Study Challenges Abstinence-Only Framework

The second presentation emerged from a collaboration between Indivior and Virginia Tech researchers examining remission as a treatment outcome. The provisional findings from the Remission from OUD as a Treatment Endpoint (ROUTE) Study followed 443 participants who had started treatment with extended-release buprenorphine within the previous three months, tracking their progress for up to one year.

The study defined remission as the absence of DSM-5 diagnostic criteria for opioid use disorder except for craving—a more nuanced standard than simple abstinence. This definition acknowledges that recovery involves more than just stopping drug use; it encompasses improvements in symptoms, functioning, and quality of life.

Participants who entered the study already in remission for three months showed markedly better outcomes across multiple measures. They reported lower craving intensity, reduced withdrawal symptoms, less pain, better overall quality of life, and lower rates of unemployment compared to participants not in remission. These findings suggest that achieving remission status represents a genuine inflection point in recovery, associated with tangible improvements in daily functioning.

Perhaps most interestingly, the study found that opioid misuse and remission status were not always consistent. Some individuals abstained from opioid misuse without yet meeting criteria for three-month remission, while others showed patterns of use that did not rise to the level of misuse despite not being completely abstinent. This complexity underscores why remission may serve as a more clinically meaningful treatment endpoint than abstinence alone.

Implications for Treatment Access and Policy

The ASAM presentations arrive at a moment of both progress and uncertainty in American addiction treatment. On one hand, the past year has seen overdose deaths decline by approximately 19 percent since their August 2023 peak—the longest sustained decrease in more than four decades. Expanded access to medication-assisted treatment, including the elimination of the X-waiver requirement for buprenorphine prescribing and permanent authorization of telemedicine, has helped more people access evidence-based care.

On the other hand, proposed federal budget cuts and the threatened consolidation of SAMHSA into a new Administration for Healthy America have created anxiety among treatment providers about whether these gains can be sustained. The real-world data presented at ASAM provides additional ammunition for advocates arguing that medication-assisted treatment represents a sound investment with measurable returns in lives saved and recovery achieved.

The Ontario study's finding that extended-release buprenorphine showed the lowest overdose event rate among all medication options may have particular relevance for policymakers considering how to allocate limited treatment resources. While the monthly injection carries higher upfront costs than daily oral buprenorphine—typically running several hundred dollars per injection versus pennies per day for generic sublingual tablets—the overdose prevention benefits may offset these costs through reduced emergency department visits, hospitalizations, and mortality.

Practical Considerations for Patients and Providers

For patients considering treatment options, the accumulating evidence for extended-release buprenorphine offers another viable pathway to recovery. The monthly injection eliminates the daily decision-making burden of taking medication, which can be particularly valuable for individuals whose lives remain chaotic or who struggle with adherence. The formulation also reduces concerns about diversion, since the medication cannot be easily transferred to others.

However, access to extended-release buprenorphine remains uneven. Not all treatment programs offer the injection, and insurance coverage varies. Some patients prefer the flexibility of oral formulations, which allow for dose adjustments and can be discontinued more quickly if side effects emerge. The injection also requires monthly clinic visits, which may pose transportation challenges for rural residents or those without reliable vehicles.

The ROUTE study's emphasis on remission rather than abstinence as a treatment goal may also shift how clinicians and patients conceptualize success. Traditional addiction treatment often focused on complete abstinence from all psychoactive substances as the only acceptable outcome. The recognition that remission—defined by symptom control and functional improvement—represents a meaningful achievement may reduce the all-or-nothing thinking that leads some patients to abandon treatment after a single lapse.

Looking Ahead

The ASAM 2026 data adds to a growing literature suggesting that long-acting formulations of buprenorphine represent a genuine advance in addiction medicine. As with any medication, individual responses vary, and no single treatment works for everyone. But the real-world evidence of reduced overdose risk and the demonstration that remission produces measurable quality-of-life improvements provide clinicians and patients with valuable information for making informed treatment decisions.

For the more than two million Americans currently living with opioid use disorder, and for the thousands more who will develop the condition this year, the availability of multiple effective medication options—including extended-release formulations that reduce daily treatment burden—represents progress worth acknowledging even as the broader policy environment remains uncertain.